Skip to content

CEDIA N-Acetylprocainamide Assay

by Boehringer Mannheim Corp. 510(k)

Active United States

510(k) K963306

Regulatory status

as of 29 Oct 2026

RegionAuthorizationNumberDateStatus
United StatesFDA 510(k)SESE Substantially Equivalent · Traditional NumberK963306 Date29 Oct 1996ClearedStatusActive

Coverage

1 jurisdiction

United States of America
  • Active
  • Expiring
  • Withdrawn
  • Listed
  • Not covered

United States — FDA 510(k) Active

Recalls

0 recalls · FDA

No FDA recalls on record, checked 6 Oct 2026.

Specification

510(k)

510(k) Number
FDA Product Code
LAR
Device Class
Class II
Regulation
21 CFR Part 862.3320
Advisory Committee
Clinical Toxicology
FDA Decision
SESE Substantially Equivalent

Overview

AI-generated summary, 1 Oct 2026

Written by a language model from registry data. Not verified by deviCERTS or the manufacturer. The registry data above is the record.

The CEDIA N-Acetylprocainamide Assay is an in vitro diagnostic medical device intended for the quantitation of N-Acetylprocainamide in human serum or plasma. It is classified as an Enzyme Immunoassay for Procainamide and operates under product code LAR.

This device is supplied as a Class II medical device with special controls and was cleared by the FDA on October 29, 1996 under 510(k) number K963306. It is manufactured by Boehringer Mannheim Corp. in Concord, CA, and is intended for use in clinical toxicology settings. The device is not specified as single-use or reusable, and no information regarding sterility, MRI safety, or storage conditions is provided.

Other devices from Boehringer Mannheim Corp.

See all devices from Boehringer Mannheim Corp. →

Questions

AI-generated answers, 1 Oct 2026

Written by a language model from registry data. Not verified by deviCERTS or the manufacturer. The registry data above is the record.

  • What is the CEDIA N-Acetylprocainamide Assay used for?

    This in vitro diagnostic device is designed for the quantitation of N-Acetylprocainamide in human serum or plasma, specifically intended for use in clinical toxicology settings to monitor drug levels.

  • How is the CEDIA N-Acetylprocainamide Assay supplied?

    The device is supplied as a Class II medical device with special controls. It is manufactured by Boehringer Mannheim Corp. in Concord, CA, and is not specified as single-use or reusable in the provided information.

  • What is the regulatory status of the CEDIA N-Acetylprocainamide Assay?

    This device was cleared by the FDA on October 29, 1996 under 510(k) number K963306, classified as substantially equivalent to predicate devices for the quantitation of N-Acetylprocainamide in human serum or plasma.

  • What is the product code and classification of this assay?

    The CEDIA N-Acetylprocainamide Assay operates under product code LAR and is classified as an Enzyme Immunoassay for Procainamide, with FDA clearance indicating it meets safety and effectiveness requirements for its intended use.